The primary purpose of the LAA-CLOSURE trial is to assess the efficacy and safety of prophylactic surgical closure of LAA in the prophylactic stroke prevention in patients undergoing aortic valve replacement (AVR) with a bioprosthesis who do not have AF prior to operation ( ID NCT02321137).

This ongoing randomized controlled prospective open-label international multicenter trial will enrol 1040 patients undergoing aortic valve replacement with CHA 2 DS 2 -VASC score ≥2 but without an indication for anticoagulation at the time of enrolment. Patients will be randomized in 1:1 fashion to standard therapy + surgical closure of LAA vs. standard therapy alone. The primary end point is a composite of incidence of stroke/transient ischemic attack, systemic embolism and cardiovascular mortality at five years follow-up.